Recruiting

Testing a New Cancer Drug for Advanced Solid Tumors

Plain-English translation of NCT06380816 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This is an early-stage trial testing a new medication called for people with advanced cancer. The trial has two main parts: first, researchers will carefully increase the dose to find the safest and most effective amount, then they will test whether the medication works alone or combined with other cancer drugs.

is a completely new treatment that has never been given to humans before. Laboratory research suggests it may work against certain cancers, and this trial will see if it is safe and effective in actual patients.

Do you qualify?

You likely qualify if…

you have advanced solid cancer (such as lung, colorectal, breast, ovarian, pancreatic, or head and neck cancer) that has not responded to standard treatments
you are at least 18 years old (some younger participants aged 16–17 may be eligible later)
your overall health is good enough to tolerate the treatment (Eastern Cooperative Oncology Group status of 0 or 1)
you have a life expectancy of at least 12 weeks
your blood work and organ function tests are within acceptable ranges
you are able to provide a tissue sample (biopsy) from your cancer before starting treatment

You likely don't qualify if…

you have received chemotherapy, immunotherapy, or other cancer treatments in the past 4 weeks
you are experiencing moderate to severe side effects from previous cancer treatments
you have active, untreated, or rapidly worsening brain tumors
you are pregnant, breastfeeding, or planning to become pregnant during the trial
you have a history of certain serious infections or organ problems that would make this treatment unsafe

What participation looks like

You will visit the hospital or clinic regularly to receive the medication and have blood tests, scans, and check-ups to monitor how your body responds. In the first part of the trial, small groups receive increasing doses to find the right amount; in the second part, more participants receive the selected dose, either alone or combined with other cancer drugs. You will also have tissue samples taken before and during treatment to help researchers understand how the medication is working.

AI-generated summary from trial data · Jun 4, 2026 · Not medical advice

Trial locations(4 sites)

United Kingdom

Guy's Hopsital, London

The Christie NHS Foundation Trust, Manchester

The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne

University Hospital Southampton NHS Foundation Trust, Southampton